Jenifer Fortney, PA
Medical · Fort Wayne, INNPI 1073963351
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $22,250 of the $26,363 with a category attached, or 84.4%. It is spread thinly across 35 manufacturers, the largest accounting for just 22.8% — the pattern of someone who eats at a lot of different presentations. Among medical clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,143 payments — averaging $23.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$6K
- AbbVie$5K
- Sun Pharmaceutical Industries Inc.$2K
- Johnson & Johnson$2K
- Regeneron Healthcare Solutions, Inc.$1K
- Novartis$1K
- plus $9K from 29 others
What the payments were for
- Consulting fees$3,57614%
- Food & beverage$22,25084%
- Education$5372%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 162 | $6,016 |
| AbbVie | 237 | $5,090 |
| Sun Pharmaceutical Industries Inc. | 76 | $2,068 |
| Johnson & Johnson | 123 | $1,596 |
| Regeneron Healthcare Solutions, Inc. | 39 | $1,385 |
| Novartis | 79 | $1,253 |
| Incyte Corporation | 37 | $1,051 |
| Sanofi | 31 | $1,030 |
| LEO Pharma Inc. | 60 | $970 |
| Lilly USA, LLC | 28 | $693 |
| E.r. Squibb & Sons, L.L.C. | 49 | $687 |
| Pfizer | 52 | $552 |
| Amgen | 24 | $495 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 15 | $466 |
| Arcutis Biotherapeutics, Inc. | 14 | $462 |
| Galderma Laboratories, L.p. | 31 | $459 |
| Boehringer Ingelheim | 10 | $298 |
| Mallinckrodt Hospital Products Inc. | 8 | $245 |
| Dermavant Sciences, Inc. | 12 | $233 |
| VYNE Pharmaceuticals Inc. | 5 | $183 |
| Journey Medical Corporation | 5 | $183 |
| Mayne Pharma Commercial LLC | 9 | $145 |
| Almirall LLC | 5 | $132 |
| Biofrontera Inc. | 10 | $122 |
| Springworks Therapeutics, Inc. | 1 | $121 |
| Helsinn Therapeutics (U.S.), Inc. | 8 | $120 |
| Janssen Scientific Affairs, LLC | 1 | $67 |
| Organon | 2 | $51 |
| LNHC, Inc | 3 | $50 |
| Genentech USA, Inc. | 2 | $43 |
| Sandoz | 1 | $25 |
| Organogenesis Inc. | 1 | $20 |
| Verrica Pharmaceuticals Inc. | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Nabriva Therapeutics, PLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$26,363 in reported general payments places this provider in the 95th percentile of 273 medical providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RinvoqUpadacitinib | 19 | $118,386 |
| OtezlaApremilast | 21 | $100,566 |
| Dupixent SyringeDupilumab | 14 | $52,962 |
| Dupixent PenDupilumab | 11 | $40,859 |
| Fluorouracil | 53 | $3,902 |
| Clobetasol Propionate | 50 | $2,321 |
| Tacrolimus | 15 | $1,962 |
| Clindamycin Phosphate | 27 | $1,376 |
| Imiquimod | 29 | $1,218 |
| Fluocinonide | 23 | $1,203 |
| Triamcinolone Acetonide | 72 | $853 |
| Doxycycline Hyclate | 27 | $569 |
| Minocycline Hcl | 27 | $553 |
| Econazole Nitrate | 12 | $552 |
| Fluticasone Propionate | 30 | $538 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $5,090 | $118,38619 claims |
| AmgenOtezla | $495 | $100,56621 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 273 medical providers in Indiana.
Other medical in Fort Wayne
- Meggie BeckleyIndianapolis$125K
- Jennifer ConnerIndianapolis$98K
- Brandon BoydCarmel$46K
- Karey DavisNew Castle$45K
- Sheryl NewCarmel$39K
- Lindsey GradyValparaiso$39K
- Jennifer IrwinIndianapolis$34K
- Dennae DaltonZionsville$33K
- Jordan Stemer-MirandaCrown Point$19K
- Donald BosticAustin$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.